You are here:Home-Chemical Inhibitors & Agonists-Metabolic Enzyme/Protease-Cytochrome P450 (CYPs)-ODM-208
ODM-208

Chemical Structure : ODM-208

CAS No.: 2231294-96-3

ODM-208 (Opevesostat, ODM208)

Catalog No.: PC-49349Not For Human Use, Lab Use Only.

ODM-208 (Opevesostat) is a potent, selective, orally bioavailable CYP11A1 inhibitor, inhibits the biosynthesis of pregnenolone with IC50 of 15 nM in NCI-H295R cells.

Packing Price Stock Quantity
10 mg $88 In stock
25 mg $148 In stock
50 mg $218 In stock
100 mg $358 In stock
250 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

ODM-208 (Opevesostat) is a potent, selective, orally bioavailable CYP11A1 inhibitor, inhibits the biosynthesis of pregnenolone with IC50 of 15 nM in NCI-H295R cells.
ODM-208 is CYP11A1-selective, shows >1,000 selectivity over metabolising CYP enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4).
ODM-208 is superior in steroid hormone biosynthesis inhibition compared to the non-selective CYP inhibitors ketoconazole and etomidate.
ODM-208 displays pregnenolone production inhibition with IC50 of 108 nM and 2,167 nM with NADPH and without NADPH, respectively.
ODM-208 displays rapid, complete, durable, and reversible inhibition of the steroid hormone biosynthesis in an adrenocortical carcinoma cell model in vitro, in adult non-castrated male mice and dogs, and in patients with CRPC.
ODM-208 (2 mg/kg/day, oral) treatment causes a significant and dose-dependent decrease in the plasma cortisol and testosterone concentrations in adult non-castrated Beagle dogs.

Physicochemical Properties

M.Wt 418.508
Formula C21H26N2O5S
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

2-(isoindolin-2-ylmethyl)-5-((1-(methylsulfonyl)piperidin-4-yl)methoxy)-4H-pyran-4-one

References

1. Mari Karimaa, et al. Mol Cancer Ther. 2022 Sep 21;MCT-22-0115.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: